Antibodies

26 Nov 2020 Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
25 Nov 2020 Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2
25 Nov 2020 F-star Therapeutics Announces Clearance of Clinical Trial Application for FS222
25 Nov 2020 European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
25 Nov 2020 Genmab Announces Enapotamab Vedotin Update
24 Nov 2020 Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
23 Nov 2020 Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
23 Nov 2020 Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
23 Nov 2020 Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
22 Nov 2020 Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
20 Nov 2020 Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
20 Nov 2020 BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma
20 Nov 2020 SynOx Therapeutics raises €37M in Series A Financing
20 Nov 2020 Imfinzi approved in the US for less-frequent, fixed-dose use
20 Nov 2020 Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
19 Nov 2020 PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314
19 Nov 2020 Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA
19 Nov 2020 Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat
18 Nov 2020 Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
17 Nov 2020 BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis
17 Nov 2020 XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development
17 Nov 2020 Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
17 Nov 2020 Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
17 Nov 2020 Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer
17 Nov 2020 Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top